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We tested the ability of Fourier Transform (FT) InfraRed (IR) microspectroscopy (microFTIR) in 
combination with unsupervised Hierarchical Cluster Analysis (HCA) in identifying drug-
resistance/sensitivity in leukemic cells exposed to tyrosine kinase inhibitors (TKIs). Experiments were 10 
carried out in a well established mouse model of human Chronic Myelogenous Leukemia (CML). Mouse-
derived pro-B Ba/F3 cells transfected with and stably expressing the human p210BCR-ABL drug-sensitive 
wild-type BCR-ABL or the V299L or T315I p210BCR-ABL drug-resistant BCR-ABL mutants were separately 
exposed to imatinib-mesylate (IMA) or dasatinib (DAS). MicroFTIR was carried out at the Diamond IR 
beamline MIRIAM where the mid-IR absorbance spectra of individual Ba/F3 cells were acquired using 15 
the high brilliance IR synchrotron radiation (SR) via aperture of 15x15 µm2 in sizes. Conventional IR 
source (globar) was used to compare average spectra over 15 cells or more. IR signatures of drug actions 
were identified by supervised analyses in the spectra of TKIs-sensitive cells. Unsupervised HCA applied 
to selected intervals of wavenumber allowed to classify the IR patterns of viable (drug-resistant) and 
apoptotic (drug-sensitive) cells with an accuracy >95%. The results from microFTIR+HCA analysis were 20 
cross-validated with those obtained via immunochemical methods, i.e. immunoblotting and flow 
cytometry (FC) that resulted directly and significantly correlated. We conclude that this combined 
microFTIR+HCA method potentially represents a rapid, convenient and robust screening approach to 
study the impact of drugs in leukemic cells included peripheral blasts from patients in clinical trials with 
new anti-leukemic drugs.25 
Introduction 
Increasing knowledge on the molecular pathogenesis of chronic 
myelogenous leukemia (CML) has resulted in the development of 
new therapeutic molecules able to improve the outcome in CML 
patients.1 30 
 Imatinib-mesylate (IMA) is the prototype compound of 
tyrosine kinase inhibitors (TKIs) targeting the abnormal tyrosine 
kinase (TK) activity associated to the kinase domain (KD) of Bcr-
Abl oncoproteins (p190, p210, or p230 kDa, respectively). Bcr-
Abl is the product of the BCR-ABL chimeric fusion gene (the 35 
Philadelphia chromosome, Ph+) derived from a reciprocal 
translocation between the breakpoint cluster region (BCR) gene 
located on chromosomes 22 and the c-Abl gene (ABL) located on 
chromosome 9 in the multi-potent bone marrow stem cell. The 
presence of Ph+ in CML cells confers growth factor independence 40 
and resistance to apoptosis allowing the progressive expansion of 
leukemic cell populations in the bone marrow during chronic 
phase.2 IMA has proved to be effective in inducing hematologic 
and cytogenetic remission in most CML patients. Unfortunately, 
a significant percentage of them tend to develop both primary and 45 
secondary resistance to IMA often leading to treatment failure. 
The clinical transition from chronic to blast phase is characterised 
by the high numbers of CML blast cells with additional changes 
in the Bcr-Abl KD that circulate in the blood of those patients and 
associate with more clinically aggressive and drug-resistant 50 
phenotypes.3 Second-third generation TKIs such as Dasatinib 
(DAS),4 nilotinib,5 and bosutinib6 have activity against many Bcr-
Abl mutants except T315I mutation for which new drug 
molecules are in the development pipeline. 7,8 
 Most popular molecular predictors of drug response in CML 55 
patients are the BCR-ABL transcript levels measured by real-time 
quantitative PCR, the Bcr-Abl KD mutation analysis, and the 
monitoring of Bcr-Abl activity.9-12 Major drawbacks are the poor 
standardisation and high costs of molecular methods for 
monitoring patients. Sometime genome expression profiling is 60 
unable to identify reproducible signatures of drugs and/or to 
predict drug-resistance in CML patients.13 Therefore, it is of great 
interest the development of new reliable and cost-effective 
methods to obtain rapid and accurate information on the 
sensitivity of CML cells to TKIs. 65 
 The present work aims at exploring whether Fourier transform 
(FT) infrared (IR) microspectroscopy (microFTIR) in 
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combination with methods for pattern recognition, i.e. 
unsupervised hierarchical cluster analysis (HCA), could represent 
a new and convenient analytical approach to obtain information 
on the sensitivity and resistance of CML cells to TKIs. 
MicroFTIR has the advantages of being a non-destructive, higly 5 
sensitive and specific analytical technique to detect molecular 
changes. In a few seconds it provides specific and spatially 
resolved biochemical information about molecular constituents 
within individual cells.14,15 In association with advanced 
chemometrics methods, microFTIR has already shown potential 10 
applications in histopathology, cell biology, and cell 
pharmacology.16-23 
Methods 
Ba/F3 cells 
Experiments with TKIs were carried out in a well established 15 
mouse-derived Ba/F3 cell model of human Ph+ CML consisting 
of drug-sensitive cells and drug-resistant mutants.24 
 Mouse pro-B Ba/F3 cells (parental, par-Ba/F3) transfected 
with and stably expressing the human p210BCR-ABL drug-sensitive 
wild-type BCR-ABL (wt-Ba/F3) or the V299L or T315I p210BCR-20 
ABL drug-resistant BCR-ABL mutants (V299L- and T315I-Ba/F3, 
respectively) were grown under sterile conditions in a humidified 
atmosphere with 5% CO2 and in RPMI 1640 medium added with 
2 mmol L-1 L-glutamine, 10% foetal bovine serum (FBS), and no 
antibiotic. Parental Ba/F3 was the BCR-ABL negative control cell 25 
line used to test the non specific toxicity of TKIs. WEHI-B3 
conditioned supernatant was added to the RPMI medium (10% 
v/v) as a source for interleukin 3 (IL-3) which is necessary to 
grow par-Ba/F3.25 Wild-type Ba/F3 cells and V299L- and T315I-
Ba/F3 cell mutants were selected and expanded in RPMI medium 30 
with no IL-3. Wild-type Ba/F3 cells are sensitive to the pro-
apoptotic actions of both IMA and DAS. The V299L-Ba/F3 cell 
mutant is sensitive to IMA and resistant to DAS, whereas T315I-
Ba/F3 cell mutant is resistant both to IMA and DAS, respectively. 
Tyrosine Kinase Inhibitors (TKIs) 35 
Imatinib-mesylate (IMA) is the 4-[(4-methylpiperazin-1-
yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2yl)amino]-
phenyl]-benzamide compound, also known as CGP057148B and 
STI571 from Novartis Pharma AG, Basel.26 IMA was dissolved 
(w/v) in sterile H2O to obtain a 10 mmol L-1 IMA stock solution 40 
that is stable at -20°C and in the dark for some weeks. Blocking 
the binding of ATP to the KD of Bcr-Abl, IMA inhibits the 
associated TK activity, restores the sensitivity of CML cells to 
pro-apoptotic factors and induces cell apoptosis. 
 Dasatinib (DAS), from Bristol-Myers Squibb BMS-354825 45 
(N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-
piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole 
carboxamide monohydrate, is a dual-specific inhibitor of Src and 
of both active and inactive conformations of Abl.27 DAS (17.2 
mg) was dissolved in 1 mL DMSO to obtain a 35.2 mM DAS 50 
stock solution and aliquots were stored at -20°C. 
 In time-course experiments with TKIs, 2.5x106 Ba/F3 cells and 
mutants suspended in 1.5 mL RPMI medium were separately 
exposed for 24 or 48 hours to 2.0 µM IMA or 16.0 nM DAS, 
respectively. Appropriate control samples (CTRLs) with no 55 
added drug or with DMSO diluted in the growth medium (v/v 
1/2000) as in DAS-treated samples were also prepared. All 
experiments were performed at least in triplicate. 
Sample preparation. 
At the end of incubation, a volume of 0.5 mL of 4% buffered-60 
paraformaldehyde (PFA) solution was added to 1.5 mL Ba/F3 
cells suspension. Cells were fixed in 1% PFA for at least 30 min., 
pelleted by centrifugation (65g for 2 min.) and re-suspended 
twice in H2O. A drop (10 µL) of each cell suspension was 
carefully deposited and air-dried on 50x25x2 mm ZnSe polished 65 
crystal to obtain an array of sample spots with cells spread in 
monolayer (ESI: Fig. S1).28 
FTIR absorbance microspectroscopy (microFTIR). 
The IR absorbance spectra were acquired at Diamond Light 
Source (DLS, UK) at the B22 IR beamline Multiband Infrared 70 
Imaging and Microspectroscopy (MIRIAM).29 Two IR sources 
were used: the highest brilliance synchrotron radiation (SR) for 
single cell analysis and the globar for average measurements on 
larger areas. In both cases the mid-IR spectral region between 
4000 cm-1 and 400 cm-1 was used. 75 
 In a typical SR microFTIR experimental setting in 
transmission modality, we used the Bruker 80V interferometer 
coupled with a Hyperion 3000 Vis-IR microscope equipped with 
36x magnification objective (N.A. 0.6) and identical condenser 
optics; a high sensitivity liquid nitrogen cooled Mercury-80 
Cadmium-Telluride (MCT) detector was used in combination 
with a Ge filter. To acquire the IR absorbance spectra of 
individual cells, samples were positioned under the objective and 
the four blade slits of the microscope were restricted to aperture 
values of 15x15 µm2 fitting the sizes of a cell (diameter 12-15 85 
µm). To optimize microFTIR performed with the broadband 
globar as more conventional IR source, the average absorbance 
spectra representative of about 15-20 cells were acquired from 
several areas of 50x50 µm2 in sizes within the sample and IR 
signals were collected. To obtain the necessary signal to noise 90 
ratio (S/N) in the spectra a number of 256 scans by scanner 
velocity of 40 kHz were performed in continuous mode at 
spectral resolution of 4 cm-1 both on the sample and the 
background (clean ZnSe substrate area). This is equivalent to a 
spectrum within 60 seconds. 95 
Pre-processing 
Using different functions in OPUS™ 6.5 software (Bruker Optik 
GmbH, Ettlingen, Germany), atmospheric and water vapour 
interferences were compensated and background intensity 
changes were corrected (concave rubberband correction) within 100 
the selected 3800-800 cm-1 interval of wavenumbers (wnrs). To 
minimize the effects of different thickness within sample and 
among samples, spectra were pre-processed with vector 
normalization function and the second derivative spectra were 
calculated with a simultaneous smoothing based on Savitzky-105 
Golay algorithm on 9 smoothing points. Signal to noise ratio 
(S/N) was systematically calculated as transmission signal versus 
root mean square value of the noise within the 2600-2400 cm-1 
interval. 
Supervised analyses 110 
Number, position and shape of marker peaks were identified and 
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compared in the spectra. The position of two peaks was 
considered significantly shifted when the difference exceeded the 
value of spectral resolution (>4 cm-1). The second order 
derivative was analysed in corresponding absorbance spectra to 
identify band and sub-band components within marker peaks. 5 
They were assigned according to the so called group frequency 
approach which associates the absorbance of specific functional 
groups in molecules with well defined vibrational frequencies 
reported in the literature.30 In quantitative analysis we compared 
the mean values of integral calculated by drawing a straight line 10 
between the two frequency limits delimiting the selected marker 
peak/region. 
Unsupervised Hierarchical Cluster Analysis (HCA) 
In hierarchical cluster analysis (HCA) with no assumption, one or 
more sub-regions within the spectra of a dataset are input to a 15 
clustering algorithm that pools them into groups based solely on 
their similarity to one other. Although the number of groups and 
the criterion by which similarity is defined (i.e., Euclidean 
distance) must be chosen, the resulting output is a non-subjective 
grouping of the spectra.31 20 
 HCA was applied to one or more selected intervals of wnrs in 
the FTIR spectra pre-processed with vector normalization and 
second derivative. Typically, the 1760-1480 cm-1 interval was 
selected to recognize the IR pattern of viable and apoptotic cells 
whereas the 1150-900 cm-1 interval was used to group the spectra 25 
according to changes in phosphate signals, respectively. Initially, 
a standard method merging two spectra with the smallest spectral 
distance into a cluster was applied to calculate Euclidean 
distances among the spectra of individual cells. Then, Ward’s 
algorithm calculated spectral distances between this newly-30 
created cluster and all the other spectra or clusters. All spectra 
grouped in each of the two final classes with the highest 
heterogeneity value were averaged to obtain the representative 
spectrum of corresponding final class.32 
Independent cross-validation of IR data analyses 35 
We applied immunomethods to measure the degrees of protein 
phosphorylation and apoptotic processes in Ba/F3 cells of 
replicate samples. The results were compared with those obtained 
from IR analyses in the spectra.28 
 The expression of Bcr-Abl and the degrees of protein 40 
phosphotyrosine were studied in Ba/F3 cell lysates adjusted to 1.0 
mg total protein mL-1. Samples (20 µL) were separated on 10% 
acrylamide/bisacrylamide gel, electroblotted on polyvinylidene 
difluoride (PVDF) membranes and probed with a mixture of 
4G10 and PY99 anti-phosphotyrosine antibodies (from Upstate 45 
Biotechnology, Waltham, and Santa Cruz Biotechnology, Santa 
Cruz, USA, respectively). After a second incubation with HRP 
conjugated secondary antibodies, the complex was visualized by 
enhanced chemi-luminescence (ECL detection system, 
Amersham, NJ, USA). After stripping, PVDF membrane was 50 
incubated with anti-c-Abl sc-887 (Santa Cruz Biotechnology, 
Santa Cruz, USA) probing Bcr-Abl and anti-actin as a control of 
constitutive protein expression in cells. 
The mean percentages of viable and apoptotic Ba/F3 cells were 
determined by flow cytometric (FC) analysis of fluorescence in 55 
cells stained with e-Fluor 450 for Annexin-V (eBioscience, Inc. 
San Diego, CA, USA) and Propidium Iodide (PI) vital dye as 
previously reported.28 The unsupervised pattern recognition 
approach resulted cross-validated when the results of HCA and 
FC analyses were in agreement. 60 
Statistics 
According to results distribution, parametric and/or non 
parametric statistics were applied to test hypotheses on the means 
and/or the medians, respectively. The α value was set to 0.05 and 
the level of significant difference to P< 0.05. 65 
Results 
Representative FTIR absorbance spectra of untreated CTRLs 
(blue traces) and of Ba/F3 cells and mutants exposed for 48 hours 
to 2.0 µM IMA (red traces) are shown in Fig. 1, respectively. 
Some differences between wt- and V299L-Ba/F3 cells exposed to 70 
IMA and corresponding untreated CTRLs can be immediately 
appreciated within the 1760-1480 cm-1 and 1150-900 cm-1 
interval. Opposite, the spectra of Bcr-Abl negative par-Ba/F3 
cells and of drug-resistant Bcr-Abl mutant T315I-Ba/F3 exposed 
to IMA are very similar to those of their untreated CTRLs. 75 
 Marker peaks within the 3000-2800 cm-1 interval in Fig. 1A 
mainly reflect the N-H stretching vibration of protein amide A 
(νmax3290 cm-1) and amide B (νmax3060 cm-1), and the anti-
symmetric and symmetric C-H stretching vibration from CH3 
(νmax2956 cm-1 and νmax2872 cm-1) and CH2 (νmax2925 cm-1 and 80 
νmax2853 cm-1) groups in lipids, respectively. Within the 1800-
900 cm-1 interval (Fig. 1B) we identified and assigned the 
following spectral components according to the data published in 
the literature.33-35 The shoulder at νmax1740 cm-1 was mainly 
assigned to the C=O stretching vibration of esters in membrane 85 
phospholipids although it can also reflect changes in the 
protonation of aspartic and glutamic acid. The most prominent 
peaks within the 1700-1480 cm-1 interval mainly reflect the 
absorbance of amide I (νmax1650 cm-1) and amide II (νmax1540 
cm-1) in proteins, respectively. The region of amides is sensitive 90 
either to the hydration level in sample and to changes in the 
secondary structures of proteins. Purging samples with nitrogen 
minimised the variability related to the hydration level in samples 
as well as the interference of free water was subtracted from the 
spectra by an appropriate algorithm allowing to compare changes 95 
in the secondary structures of proteins among samples. In 
particular, α-helical structures contribute with a component at 
νmax1650 cm-1, aggregated β-sheet structures absorb at νmax1628 
cm-1, and tyrosine residues in proteins have a components at 
νmax1512 cm-1. The anti-symmetric scissoring of CH3 in lipids 100 
and proteins and the C=O stretching vibrations of COO- in fatty 
acids and amino acid side chain absorb at νmax1450 cm-1 and at 
νmax1400 cm-1, respectively. The two major absorbance peaks 
within the 1300-1000 cm-1 interval originate from the anti-
symmetric (νmax1240 cm-1) and symmetric (νmax1086 cm-1) 105 
stretching of PO2- groups in nucleic acids DNA and RNA. 
However, also other phosphate groups such as COP in 
phospholipids (νmax1086 cm-1) as well as the vibrations of applied 
to the 1760-1480 cm-1 and 1150-900 cm-1 intervals CH2OH 
groups (νmax1056 cm-1) and of COH groups (νmax1020 cm-1) in 110 
carbohydrates may contribute to the shape of marker peak with 
limits 1140-990 cm-1. The stretching vibrations of CC and CO 
functional groups in the deoxyribose and phosphate moieties of  
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Fig. 1 Supervised analyses in the representative FTIR absorbance spectra of mouse-derived Ba/F3 cells model of human chronic myeloid leukemia 
(CML). A. Normalized and baseline corrected spectra are shown within the 3800-800 cm-1 interval of wnrs (omitted 2700-1800 cm-1 interval). Blue traces: 
untreated control (CTRL); red traces: samples exposed to 2.0 µM imatinib mesylate (IMA) for 48 hours. B. The corresponding second order derivative 
spectra within the 1800-900 cm-1 interval. Typical IR signatures of cell apoptosis induced by IMA have been marked with grey lines. 5 
DNA backbone have been reported to occur also at νmax965 cm-1 
whereas the small peaks at νmax950 cm-1 and at νmax915 cm-1 have 
been assigned also to the absorbance of PO32- in phosphorylated 
proteins. Although the univocal interpretation of pre-assigned IR 
signals cannot be always obtained, the 1800-900 cm-1 interval is 10 
generally considered as a “fingerprinting” useful to classify the 
pattern of individual cells by the means of appropriate algorithms. 
 We optimised microFTIR setup in order to achieve appropriate 
signal to noise (S/N) values in the spectra at the necessary spatial 
resolution. In fact, the high flux of IR photons released at the 15 
sample plane by the narrowed beam from the highest brilliance 
SR IR source is within the MCT detector dynamic range and 
enhances the IR signals from the cell restricted within 15x15 µm2 
(or lower) aperture slits well above the background noise. 
Therefore, the S/N value in the SR spectrum results appropriate 20 
(S/N = 6500). On the contrary, over the same sample area by the 
isotropic and broad globar source, lower S/N values are achieved 
in the spectrum (S/N = 1300) as expected (ESI: Fig. S1). Lower 
S/N values increase the uncertainty in revealing thus assigning 
bands and sub-bands, i.e., within the region of phosphate signals, 25 
and reduce also the probability to classify spectra by 
unsupervised HCA correctly. Considering that globar is the 
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conventional IR source for routine applications we optimised 
microFTIR using a broadband MCT setting the aperture slits of 
the microscope to delimit spot areas of 50x50 µm2 in sizes. Over 
homogeneous zones of the sample (Fig. S1), we could obtain 
spectra of quality similar to those of individual cells by SR 5 
microFTIR. IR signals could be identified and assigned by 
supervised method within and unsupervised HCA applied to the 
1300-900 cm-1 interval of wnrs (Fig. S1, middle). 
 
Fig. 2 Unsupervised recognition of IR patterns by hierarchical cluster analysis (HCA). A. HCA was applied to the 1760-1480 cm-1 interval of SR FTIR 10 
absorbance spectra of individual cells in untreated CTRL, and DAS- or IMA-treated (24 or 48 hours) samples of wt-, V299L-, and T315I-Ba/F3 cells (24 
hrs has been omitted). B. The representative spectra averaging those of individual cells grouped in each of the two final classes are shown according to the 
condition of drug treatment: blue, untreated CTRL; pink, 16.0 nm DAS; red, 2.0 µM IMA. The corresponding second derivatives have been superimposed 
to highlight spectral differences between drug-sensitive (SENS) and drug-resistant (RES) cells as compared to those of untreated CTRL (blue). C. The 
cross-validation of HCA by flow cytometry (FC). Dot-plots of Annexin-V to Propidium Iodide (P.I.) staining in Ba/F3 cells and mutants exposed to 16.0 15 
nM DAS or 2.0 µM IMA for 24 and 48 hours, respectively. The relative percentages of viable cells (V), of cells in early and late apoptosis (EA, A, 
respectively), and of necrotic cells and debris (N&D) measured in a typical time-course experiment with drugs have been reported. 
Supervised identification of IR markers of TKIs interference 
with cell growth processes 
Using the supervised group frequency approach we recognised 20 
some typical IR signatures related to apoptotic processes in 
cells.28,36-42 As compared to untreated CTRL (blue traces in Fig. 
1), the peaks of amide I and amide II are significantly shifted 
towards lower wnrs in the absorbance spectra of drug-sensitive 
Ba/F3 cells and mutants exposed to IMA (red traces of wt- and 25 
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V299L-Ba/F3 cells in Fig. 1, respectively) whereas they coincide 
in the spectra of drug-resistant cells (red traces of par- and T315I-
Ba/F3 cells in Fig. 1). Vibrational changes are more evident in 
the second derivative spectra (Fig. 1B) where both the decreased 
absorbance of component assigned to α-helical structures 5 
(νmax1650 cm-1) and the increased absorbance of component 
assigned to aggregated β-sheet structures (νmax1628 cm-1) 
contribute to the shift of amide I normally peaking at νmax1650 
cm-1 in untreated CTRL towards νmax1640 cm-1 (or lower) wnrs in 
the spectra of apoptotic cells, respectively. In a similar manner, 10 
the increased absorbance of component assigned to tyrosine 
residues in proteins (νmax1512 cm-1) modifies the shape of the 
peak of amide II that consequently shifts from νmax1540 cm-1 in 
the spectra of CTRL to νmax1530 cm-1 wnrs in the spectra of 
apoptotic cells. Sometimes cells undergoing apoptosis show more 15 
pronounced absorbance values at νmax1740 cm-1 mainly reflecting 
the increased CO stretching in membrane phospholipids. 
 We assumed that the spectral features of viable and apoptotic 
cells could reflect drug-resistance and drug-sensitivity in Ba/F3 
cells and mutants exposed to TKIs, respectively. 20 
Unsupervised pattern recognition by HCA 
Fig. 2 illustrates the results obtained with the application of 
unsupervised HCA to individual SR FTIR spectra of Ba/F3 cells 
within the 1760-1480 cm-1 interval of wnrs (Fig. 2A). The 
representative IR patterns of viable untreated CTRLs (blue) and 25 
of Ba/F3 cells and mutants with IR patterns of drug-sensitivity 
(SENS) and drug-resistance (RES) in samples exposed for 24 and 
48 hours to 16.0 nM DAS (pink) or to 2.0 µM IMA (red) are 
shown in Fig. 2B, respectively. The results of a representative 
experiment of FC analysis to quantify the relative percentages of 30 
viable (V) and apoptotic (EA and A) Ba/F3 cells in samples are 
shown in Fig. 2C. 
wt-Ba/F3 cells 
In the dendrogram of 24 hours cell treatment HCA groups in the 
first class the spectra of 2% DAS- and of 2% IMA-treated cells 35 
(pink and red, respectively) together with the spectra of 98% 
untreated CTRL (blue). The second class contains the spectra of 
2% untreated CTRL (blue), 98% DAS-treated (pink) and 98% 
IMA-treated (red) cells, respectively. These two final classes 
have a distance of 26.1. In the dataset of cells exposed for 48 40 
hours to TKIs, HCA classifies the spectra of 99% untreated 
CTRL, 1% DAS and 1% IMA-treated cells in the first class, and 
of 1% untreated CTRL, 99% DAS-treated and 99% IMA-treated 
cells in the second class, respectively. The distance between the 
two classes results 44.6. As compared to the representative 45 
average spectra of CTRL wt-Ba/F3 cells (blue traces), the 
average spectra of DAS- and IMA-treated Ba/F3 cells grouped by 
HCA show the typical IR pattern of apoptotic cells with IR 
signatures that can be easily identified in the corresponding 
second derivative spectra (Fig. 2B pink and red traces, 50 
respectively). The percentages of viable and apoptotic cells 
identified by FC analysis (Fig. 2C) were in agreement with those 
of HCA. 
V299L-Ba/F3 cells 
Most spectra of V299L-Ba/F3 cells exposed for 24 and 48 hours 55 
to DAS (Fig. 2A, pink traces) are grouped by HCA with those of 
corresponding untreated CTRLs (blue) and their spectra have 
very similar IR patterns (Fig. 2B, pink and blue traces, 
respectively). On the contrary, the spectra of V299L-Ba/F3 cells 
exposed for 24 and 48 hours to 2.0 µM IMA are mostly grouped 60 
by HCA in distinct classes. Typical IR markers of cell apoptosis 
are not present in the representative spectra of DAS-treated 
V299L-Ba/F3 cells resulting therefore with an IR pattern of 
resistance (RES) to the pro-apoptotic action of this TKI. On the 
contrary, typical IR markers of cell apoptosis are present in the 65 
spectra of V299L-Ba/F3 cells treated with IMA and indicate the 
sensitivity (SENS) of this mutant cell clone to the actions of this 
TKI. The results of FC analysis confirmed those of HCA. 
T315I-Ba/F3 cells 
The spectra of untreated CTRL (blue) and of T315I-Ba/F3 mutant 70 
cells treated for 48 hours with 16.0 nM DAS (pink) or 2.0 µM 
IMA (red) are mixed in the dendrogram of Fig. 2A (57% 
untreated CTRL, 2% DAS-treated, and 51% IMA-treated T315I-
Ba/F3 cells spectra in the first class and 43% untreated CTRL, 
98% DAS-treated, and 90% IMA-treated T315I-Ba/F3 cells 75 
spectra in the second class, respectively). Similar results were 
obtained in the dataset of spectra of T315-Ba/F3 cells exposed for 
24 hours to TKIs. According to their double drug-resistance, the 
representative spectra of T325I-Ba/F3 cells classified by HCA 
have no IR pattern of cell apoptosis (Fig. 2B)  and only a few 80 
apoptotic cells stain for Annexin-V (Fig. 2C). 
 Significant numbers of apoptotic cells (>15%) could be 
observed in samples of par- and T315I-Ba/F3 cells exposed for 
48 hours to 32 nM DAS and 8.0 µM IMA, respectively. 
Cumulative fractions of drug-resistant and drug-sensitive Ba/F3 85 
cells and mutants calculated by SR microFTIR+HCA within 
replicate experiments are shown in ESI Fig. S2. 
Supervised identification of IR signatures of TKIs 
interference with protein phosphorylation processes 
TKI treatment induces not only cell apoptosis but also the 90 
inhibition of TK activity in sensitive cells. The identification of 
signatures related to the interferences with abnormal TK activity 
can therefore represent a valuable tool useful for the early 
identification of drug-sensitivity/resistance in leukemic blasts. 
 Fig. 3 illustrates the strategy we used to identify and cross-95 
validate IR markers of protein phosphorylation in Ba/F3 cells. 
The intensity of phosphate signals reflected by the mean values of 
integral with limits 1150-900 cm-1 in the representative IR spectra 
was related to the expression/activity of Bcr-Abl and to the 
degrees of protein tyrosine phosphorylation measured in Ba/F3 100 
cells and mutants with the different levels of sensitivity to the 
inhibitory actions of IMA and DAS (Fig. 3, A through D, 
respectively). To associate the absorbance of phosphorylated 
proteins with specific wnrs, we compared the FTIR absorbance 
spectra of equimolar samples of purified bovine serum albumin 105 
(BSA) which is not a phosphorylated protein, and of ovalbumin 
(OVA) and non fat milk (NFM) which contain various degrees of 
phosphate rich proteins such as ovalbumin and caseins, 
respectively. The spectra of Fig. 3E show absorbance peaks of 
different intensity within the 1150-700 cm-1 interval of wnrs 110 
among samples. In particular, NFM has the highest and BSA the 
lowest absorbance values at νmax1070 cm-1, respectively. 
Therefore we assumed that changes in intensity of the signals 
within this interval could reflect the different content/degrees of  
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Fig. 3 Signatures of drug interference with protein phsophorylation processes in Ba/F3 cells and mutants exposed to specific Bcr-Abl tyrosine kinase 
inhibitors dasatinib (DAS) and imatinib mesylate (IMA). A-C. Immunoblotting analyses in the cell lysates (20 µL/lane adjusted to 1.0 mg total protein 
mL-1) of untreated CTRL Ba/F3 cells. A-C. lanes 1 through 4: proteins of untreated CTRL parental- (1), wild type-(2), V299L-(3), and T315I-(4) Ba/F3 
cells probed with a mixture of anti-phosphotyrosine antibodies (A), anti-Abl antibody to confirm the absence/presence of Bcr-Abl (B), and anti-actin 5 
antibody (C), respectively. D. Immunoblotting of phosphotyrosine (P-tyrosine) in the lysates of Ba/F3 cells exposed for 24 hours to 16.0 nM DAS or 2.0 
µM IMA, respectively. Untreated CTRL: lanes: 1, 4, 7, and 10; Ba/F3 cells exposed to DAS: 2, 5, 8, and 11 or to IMA: 3, 6, 9, and 12, respectively. E. 
FTIR absorbance spectra of 1.0 mM bovine serum albumin (BSA), ovalbumin (OVA), and non fat milk (NFM) pure reference substances used to identify 
IR signals from phosphoproteins within the 1500-800 cm-1 interval of wnrs. F. The comparison of mean (and error) values of integral with limits 1150-900 
cm-1 calculated in the FTIR absorbance spectra of untreated CTRLs and in par-, wt-, V299L-, and T315I-Ba/F3 cell replicates (n = 3) exposed to TKIs. 10 
phosphorylated proteins in CML cells.28,34,35 
 To test whether changes within this spectral region were in 
agreement with the inhibitory actions of IMA and DAS on Bcr-
Abl associated TK activity we compared the mean values of 
integral with limits 1150-900 cm-1 in the FTIR absorbance 15 
spectra of untreated control (CTRL) and of Ba/F3 cells replicates 
exposed to 16.0 nM DAS or 2.0 µM IMA for 24 or 48 hours, 
respectively. In Fig. 3F significant differences (mean and 
standard deviation, SD) are observed among untreated CTRL 
Ba/F3 cells and among parental- and wt-Ba/F3 cells, and V299L- 20 
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and T315I-Ba/F3 cell mutants exposed to drugs. In particular the 
values of this integral reflect those of phosphotyrosine 
determined by immunoblotting analyses shown in Fig. 3D. The 
one way analysis of variance, ANOVA carried out in 3 replicate 
experiments and 2 time points, revealed that the mean values of 5 
this integral were significantly lower in untreated CTRL par-
Ba/F3 cells (2.32 ± 0.035, n = 6; P< 0.001) as compared with 
CTRL wt- (2.63 ± 0.07), V299L- (2.62 ± 0.11), and T315I-Ba/F3 
cells (2.68 ± 0.08), respectively. Moreover, as compared to 
corresponding untreated CTRLs the mean values of this integral 10 
were significantly reduced in wt-Ba/F3 cells exposed for 24 and 
48 hours to DAS (2.16 ± 0.03 and 1.99 ± 0.04; P<0.001) or IMA 
(2.18 ± 0.12 and 2.08 ± 0.05; P=0.005) and in V299L-Ba/F3 cells 
exposed to IMA (2.2 ± 0.03 and 2.13 ± 0.03; P=0.04) but not to 
DAS (2.54 ± 0.06 and 2.51 ± 0.14). According to their double 15 
resistance, the values of this integral did not change significantly 
in the spectra of DAS- and IMA-resistant T315I-Ba/F3 cells. No 
significant difference was observed also in Bcr-Abl negative par-
Ba/F3 cells. 
 20 
Fig. 4 The unsupervised identification of drug-resistance/sensitivity in 
samples analysed by microFTIR with globar. A. HCA of 24 average 
spectra. B. Spectral differences between drug-resistant (black) and drug-
sensitive (pink and red) samples have been highlighted with gray lines. 
HCA in the spectra obtained by microFTIR with Gobar 25 
Fig.4 illustrates the performance of HCA in classifying drug-
sensitive and drug-resistant samples within a dataset of spectra 
acquired by microFTIR with globar. In the dendrogram of Fig. 
4A, 18 spectra are grouped in the first class, included all 
untreated CTRLs (n=8, blue), all par- and T315I-Ba/F3 treated 30 
cells (n=8, black), and DAS-treated V299L-Ba/F3 cells (n=2, 
black), respectively. Of the remaining 6 spectra grouped in the 
second class, 4 are those of drug-sensitive wt-Ba/F3 cells exposed 
for 24 and 48 hours to 16.0 nM DAS or 2.0 µM IMA (red), and 2 
are of V299L-Ba/F3 cells exposed to IMA for 24 and 48 hours 35 
(pink), respectively. The resulting spectra with IR patterns of 
drug-resistance and drug-sensitivity are shown in Fig. 4B with 
major differences highlighted by grey lines. As compared to the 
spectra of CTRL (blue) and drug-resistant Ba/F3 cells (black) 
samples that were grouped together by HCA, the spectra of DAS-40 
(pink) and IMA-(red) sensitive samples show typical IR markers 
of cell apoptosis within the 1760-1480 cm-1 interval and 
additional changes within the 1140-990 cm-1 interval or wnrs. In 
particular, changes at νmax1056 cm-1 (CH2OH groups ) and at 
νmax1020 cm-1 (COH groups) can suggest some interferences of 45 
drugs with the metabolism of carbohydrates, respectively. 
 
Fig. 5 Correlation observed among data obtained with two independent 
methods, SR microFTIR+HCA (y) and FC (x), measuring cell apoptosis 
in samples (means and errors of triplicates). 50 
Correlation studies 
The results of correlations studies carried out to evaluate whether 
two independent methods give concordant information are shown 
in Fig. 5. The dot-plot correlates cell apoptosis quantified in 
samples by SR microFTIR+HCA (y) and by FC analysis (x), 55 
respectively. A direct and significant linear correlation was 
calculated (n = 50, Pearson’s correlation coefficient = 0.97) and 
the line describes the following linear regression equation 
through data points: y = 1.193x - 9.671. 
Discussion 60 
The identification of reliable markers of metabolic processes 
occurring in cells is critical in the field of cell biology and has 
potential applications in drug discovery and translational 
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medicine. Since the mid-IR spectrum of a cell reflects whole cell 
biochemistry, microFTIR absorbance spectroscopy is considered 
a sensitive analytical technique to obtain complete and rapid 
information on the whole …omics of cell processes.14,15 The 
possibility to identify spectral changes reflecting the interference 5 
of drugs in cells might suggest the use of mid-IR spectrum as an 
useful biomarker.43,44 
 Although major differences observed among the spectra in Fig. 
1 can immediately suggest the presence of drug resistant samples, 
the interpretation of subtle differences cannot be obtained by the 10 
simple visual inspection and appropriate qualitative and 
quantitative analyses are required. The acceptable S/N values 
achieved in the spectra obtained with both SR and globar 
configurations allowed to perform unsupervised classification by 
HCA.17,45 Major advantage of combining mathematical and 15 
statistical methods for multivariate analysis is the suppression of 
subjective component to obtain information on drug-
resistance/sensitivity in samples. Therefore, the results of present 
work have demonstrated that the same accurate identification of 
drug-sensitive and drug-resistant cells can be obtained by SR 20 
microFTIR+HCA (Figs. 2) and, although at lower spatial 
resolution, also by microFTIR performed with globar (Fig. 4) 
which is the IR source of first choice for routine microFTIR 
analyses in samples with benchtop instrumentation. MicroFTIR 
performed with the highest brilliance SR should be preferentially 25 
used for validation of reference spectra.43 
 The possibility to combine microFTIR and computational 
approach can have several advantages toward classic biochemical 
and immunochemical approaches that are characterized by more 
complex manipulations in the samples. No particular skill and 30 
minimal manipulation required to prepare samples for microFTIR 
analysis reduces the probability of introducing artefacts that can 
influence the final results. Further advantages derive from the 
reduction of costly reagents like monoclonal antibodies that are 
extensively used to interrogate the dynamics of cell signalling or 35 
the functional status in cells. The potentially high-processivity of 
microFTIR performed with benchtop instrumentation opens the 
way to high-throughput screening and further reduction of the 
costs of individual assays. All these applications, however, rely 
on the association of IR markers with specific biochemical 40 
processes within cells. This implies the initial application of 
rigorous cross-validation procedures in order to associate specific 
changes in the IR spectra to a unique or limited set of 
biochemical, structural, and functional cellular events. 
 The results of IR analysis in the Ba/F3 cells model of human 45 
CML are in agreement with our previous findings obtained in 
human BCR-ABL positive cell lines exposed to TKIs.28 Moreover, 
the typical IR signatures of cell apoptosis in Ba/F3 cells and 
mutants that were sensitive to the actions of TKIs are the same 
that have been already reported in different cell lines.36-42 Not 50 
only we have quantified cell apoptosis in samples by SR 
microFTIR+HCA but also we made the cross-validation of IR 
signatures to use as potential references in future pre-clinical and 
clinical applications. 
 The IR spectra of purified molecules or of their mixtures have 55 
been already used to assign vibrational components by a 
supervised frequency approach in the analysis of IR spectra.34,46 
As the dynamic of cellular phosphorylation events are crucial to 
control cell signalling we have focused part of our efforts on this 
aspect. Using appropriate cellular models suited for the purpose 60 
we were able to unequivocally associate and cross-validate some 
modification within the phosphate region of mid-IR spectrum to a 
specific biochemical event involving protein tyrosine 
phosphorylation (Fig. 3). Another important aspect concerns with 
the capability to measure apoptotic/necrotic events associated to 65 
the effectiveness of drugs used. Several drug screening protocols 
rely on these parameters to select drug candidates to move 
forward toward the drug-discovery pipeline. For example, 
National Cancer Institute protocols for the preliminary in vitro 
screening expose three human cancer cell lines to a single dose of 70 
new drug for 48 hours. If the growth of one or more cell lines is 
inhibited, the drug is then probed against the full panel of 60 
human cancers. Only 2% of approximately 2,500 compounds 
tested on a yearly basis usually progress to the next stage of 
testing in mice 75 
(http://www.cancer.gov/cancertopics/factsheet/NCI/drugdiscover
y). It is evident that any improvement can bring to higher 
throughput and has an impact into making more cost/effective 
this approach as a drug-screening program. 
 The results of present study suggest that two critical 80 
parameters of interest in drug screening/testing can be evaluated 
within the IR spectrum: cell death and the levels of 
phosphorylation in proteins. As the mid-IR spectrum can reveal 
both events, microFTIR performed in samples subjected to a 
simple processing and within a single round of measurement 85 
appears an advantageous approach in comparison with analytical 
methods that evaluate only one of these parameters at the time 
(typically cell proliferation/death). Furthermore, such events can 
be evaluated at the single-cell level or at a wider cell population 
level according to the instrument setting chosen. 90 
Conclusions 
The microFTIR+HCA approach as described in the present paper 
is well suited for a drug screening program based on the 
identification of TKI/Phosphatase activators. Being able to 
identify also signature of cell death, it can be applied to a much 95 
wider range of compounds and cellular models of disease. Since 
microFTIR analysis does not damage the sample, and the 
measurement can be performed on formalin-fixed then dried 
cells, there is no room for cell alteration after drug treatment. 
Therefore, samples can also be sent to different facilities/labs for 100 
multi-centric evaluation and protocols standardization. 
 In conlcusion, this combined microFTIR+HCA approach 
requiring minimal sample handling potentially represents a 
convenient and more robust screening approach to identify drug-
resistance/sensitivity in leukemic cell lines as well as in leukemic 105 
blasts from peripheral blood of patients. 
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Fourier Transform InfraRed microspectroscopy (microFTIR) in combination with unsupervised Hierarchical 
Cluster Analysis (HCA) is a rapid, robust, and relatively inexpensive method suitable for high-throughput 
identification and classification of drug-sensitivity/-resistance in leukemic cells.  
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Supervised analyses in the representative FTIR absorbance spectra of mouse-derived Ba/F3 cells model of 
human chronic myeloid leukemia (CML). A. Normalized and baseline corrected spectra are shown within the 
3800-800 cm-1 interval of wnrs (omitted 2700-1800 cm-1 interval). Blue traces: untreated control (CTRL); 
red traces: samples exposed to 2.0 µM imatinib mesylate (IMA) for 48 hours. B. The corresponding second 
order derivative spectra within the 1800-900 cm-1 interval. Typical IR signatures of cell apoptosis induced 
by IMA have been marked with grey lines.  
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The optimisation of microFTIR analysis in samples. Two spectra of the same individual cell restricted by 
15x15 µm2 aperture slits were obtained by microFTIR performed consecutively with synchrotron radiation 
(SR) and globar as the external and internal IR sources, respectively. The significantly different signal to 
noise (S/N) values achieved in each spectrum within the 2600-2400 cm-1 interval of wavenumbers (wnrs) 
have been reported. To improve the quality of spectra acquired with globar, the aperture slits were set to 
50x50 µm2 and IR signals were collected from larger areas over homogeneous zones within samples. 
Spectra with similar quality were obtained by microFTIR with SR and globar within the 1300-900 cm-1 
interval of wnrs allowing to apply algorithms for unsupervised pattern recognition to a wide interval of wnrs. 
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Unsupervised recognition of IR patterns by hierarchical cluster analysis (HCA). A. HCA was applied to the 
1760-1480 cm-1 interval of SR FTIR absorbance spectra of individual cells in untreated CTRL, and DAS- or 
IMA-treated (24 or 48 hours) samples of wt-, V299L-, and T315I-Ba/F3 cells (24 hrs has been omitted). B. 
The representative spectra averaging those of individual cells grouped in each of the two final classes are 
shown according to the condition of drug treatment: blue, untreated CTRL; pink, 16.0 nm DAS; red, 2.0 µM 
IMA. The corresponding second derivatives have been superimposed to highlight spectral differences 
between drug-sensitive (SENS) and drug-resistant (RES) cells as compared to those of untreated CTRL 
(blue). C. The cross-validation of HCA by flow cytometry (FC). Dot-plots of Annexin-V to Propidium Iodide 
(P.I.) staining in Ba/F3 cells and mutants exposed to 16.0 nM DAS or 2.0 µM IMA for 24 and 48 hours, 
respectively. The relative percentages of viable cells (V), of cells in early and late apoptosis (EA, A, 
respectively), and of necrotic cells and debris (N&D) measured in a typical time-course experiment with 
drugs have been reported.  
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Cumulative fractions of drug-resistant (blue bars) and drug-sensitive (pink and red bars) cells identified by 
SR microFTIR+HCA in samples (mean of 3 independent experiments).  
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Signatures of drug interference with protein phsophorylation processes in Ba/F3 cells and mutants exposed 
to specific Bcr-Abl tyrosine kinase inhibitors dasatinib (DAS) and imatinib-mesylate (IMA). A-C. 
Immunoblotting analyses in the cell lysates (20 µL/lane adjusted to 1.0 mg total protein mL-1) of untreated 
CTRL Ba/F3 cells. A-C. lanes 1 through 4: proteins of untreated CTRL parental- (1), wild type-(2), V299L-
(3), and T315I-(4) Ba/F3 cells probed with a mixture of anti-phosphotyrosine antibodies (A), anti-Abl 
antibody to confirm the absence/presence of Bcr-Abl (B), and anti-actin antibody (C), respectively. D. 
Immunoblotting of phosphotyrosine (P-tyrosine) in the lysates of Ba/F3 cells exposed for 24 hours to 16.0 
nM DAS or 2.0 µM IMA, respectively. Untreated CTRL: lanes: 1, 4, 7, and 10; Ba/F3 cells exposed to DAS: 2, 
5, 8, and 11 or to IMA: 3, 6, 9, and 12, respectively. E. FTIR absorbance spectra of 1.0 mM bovine serum 
albumin (BSA), ovalbumin (OVA), and non fat milk (NFM) pure reference substances used to identify IR 
signals from phosphoproteins within the 1500-800 cm-1 interval of wnrs. F. The comparison of mean (and 
error) values of integral with limits 1150-900 cm-1 calculated in the FTIR absorbance spectra of untreated 
CTRLs and in par-, wt-, V299L-, and T315I-Ba/F3 cell replicates (n = 3) exposed to TKIs.  
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The unsupervised identification of drug-resistance/sensitivity in samples analysed by microFTIR with globar. 
A. HCA of 24 average spectra. B. Spectral differences between drug-resistant (black) and drug-sensitive 
(pink and red) samples have been highlighted with gray lines.  
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Correlation observed among data obtained with two independent methods, SR microFTIR+HCA (y) and FC 
(x), measuring cell apoptosis in samples (means and errors of triplicates).  
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